Larimar Therapeutics Management

Management Kriterienprüfungen 3/4

Larimar Therapeutics' CEO ist Carole Ben-Maimon , ernannt in May 2020, hat eine Amtszeit von 4.08 Jahren. Die jährliche Gesamtvergütung beträgt $3.14M , bestehend aus 17.8% Gehalt und 82.2% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.18% der Aktien des Unternehmens, im Wert von $903.48K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.9 Jahre bzw. 3.9 Jahre.

Wichtige Informationen

Carole Ben-Maimon

Geschäftsführender

US$3.1m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	17.8%
Amtszeit als Geschäftsführer	4.1yrs
Eigentum des Geschäftsführers	0.2%
Durchschnittliche Amtszeit des Managements	3.9yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.9yrs

Jüngste Management Updates

Recent updates

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

May 31

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Nov 13

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

May 19

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 02

Laramar Therapeutics issued patent for lead pipeline candidate

Oct 20

Larimar Therapeutics prices ~$70M stock offering

Sep 14

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Sep 02

Larimar Therapeutics GAAP EPS of -$0.47

Aug 11

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Mar 21

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Dec 18

Larimar under pressure as FDA puts clinical hold on CTI-1601 program

May 26

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 08

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Carole Ben-Maimon im Vergleich zu den Einnahmen von Larimar Therapeutics verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-US$45m
Dec 31 2023	US$3m	US$560k	-US$37m
Sep 30 2023	n/a	n/a	-US$33m
Jun 30 2023	n/a	n/a	-US$33m
Mar 31 2023	n/a	n/a	-US$33m
Dec 31 2022	US$2m	US$528k	-US$35m
Sep 30 2022	n/a	n/a	-US$35m
Jun 30 2022	n/a	n/a	-US$44m
Mar 31 2022	n/a	n/a	-US$47m
Dec 31 2021	US$2m	US$510k	-US$51m
Sep 30 2021	n/a	n/a	-US$56m
Jun 30 2021	n/a	n/a	-US$49m
Mar 31 2021	n/a	n/a	-US$48m
Dec 31 2020	US$5m	US$268k	-US$42m

Vergütung im Vergleich zum Markt: CaroleDie Gesamtvergütung ($USD3.14M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD2.45M).

Entschädigung vs. Einkommen: CaroleDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Carole Ben-Maimon (65 yo)

4.1yrs

Amtszeit

US$3,137,432

Vergütung

Dr. Carole S. Ben-Maimon, M.D., is President, Chief Executive Officer and Director at Larimar Therapeutics, Inc. since May 28, 2020. She was Chief Executive Officer, President and Director at Chondrial The...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Carole Ben-Maimon	CEO, President & Director	4.1yrs	US$3.14m	0.18% $ 793.8k
Michael Celano	Secretary & CFO	4.1yrs	US$1.42m	0.087% $ 391.3k
Gopi Shankar	Chief Development Officer	1.3yrs	US$1.43m	0.0078% $ 35.1k
John Berman	Vice President of Finance & Administration	less than a year	keine Daten	keine Daten
Jennifer Johansson	Vice President of Legal & Compliance	7.5yrs	keine Daten	keine Daten
Russell Clayton	Chief Medical Officer	less than a year	keine Daten	keine Daten
Francis Conway	VP & Controller	3.9yrs	keine Daten	keine Daten

3.9yrs

Durchschnittliche Betriebszugehörigkeit

64yo

Durchschnittliches Alter

Erfahrenes Management: LRMRDas Führungsteam des Unternehmens gilt als erfahren (3.9 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Carole Ben-Maimon	CEO, President & Director	4.1yrs	US$3.14m	0.18% $ 793.8k
Jonathan Leff	Independent Director	4.1yrs	US$79.96k	keine Daten
Jeffrey Sherman	Independent Director	less than a year	US$56.43k	0% $ 0
Frank Thomas	Independent Director	10yrs	US$86.21k	0.0031% $ 14.0k
Thomas Hamilton	Independent Director	4.1yrs	US$77.77k	0.89% $ 4.0m
Joseph Truitt	Independent Chairman of the Board	4.1yrs	US$114.96k	0.0043% $ 19.3k
Giovanni Manfredi	Member of Scientific Advisory Board	3.7yrs	keine Daten	keine Daten
Mark Payne	Member of Scientific Advisory Board	3.7yrs	keine Daten	keine Daten
Marni Falk	Member of Scientific Advisory Board	3.7yrs	keine Daten	keine Daten
Jill Ostrem	Member of Scientific Advisory Board	1.8yrs	keine Daten	keine Daten

3.9yrs

Durchschnittliche Betriebszugehörigkeit

57.5yo

Durchschnittliches Alter

Erfahrener Vorstand: LRMRDie Vorstandsmitglieder gelten als erfahren (3.9 Jahre durchschnittliche Amtszeit).

Larimar Therapeutics Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Larimar Therapeutics, Inc. Appoints Dr. Jeffery W. Sherman to its Board of Directors

Larimar Therapeutics, Inc. Announces Chief Medical Officer Changes

Larimar Therapeutics, Inc. Appoints Gopi Shankar as Chief Development Officer

High number of new and inexperienced directors

CEO, President & Director recently bought US$100k worth of stock

High number of new and inexperienced directors

Recent updates

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

United States Food and Drug Administration Selects Larimar Therapeutics, Inc. to Participate in Start Pilot Program for Nomlabofusp in Friedreich's Ataxia

Larimar Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Revenue and earnings growth

Larimar Therapeutics Announces the Dosing of the First Patient in Long-Term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’S Ataxia

New minor risk - Shareholder dilution

Larimar Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.000005 million.

Larimar Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $50 million.

Price target increased by 41% to US$16.24

Larimar Therapeutics, Inc. Reports Positive Top-Line Data from Phase 2 Dose Exploration Study from 25 Mg and 50 Mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Larimar Therapeutics, Inc. Appoints Dr. Jeffery W. Sherman to its Board of Directors

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial

Larimar Therapeutics, Inc. Announces Chief Medical Officer Changes

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

Larimar Therapeutics Reports Preliminary Top-Line Data from Phase 2 Trial’S 25 Mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’S Ataxia

Larimar Therapeutics, Inc. Appoints Gopi Shankar as Chief Development Officer

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Price target decreased to US$10.59

High number of new and inexperienced directors

Laramar Therapeutics issued patent for lead pipeline candidate

CEO, President & Director recently bought US$100k worth of stock

Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients

Larimar Therapeutics prices ~$70M stock offering

Price target increased to US$6.23

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Larimar Therapeutics, Inc. Provides Updates on CTI-1601 Clinical Program Following A Type C Meeting with the U.S. Food and Drug Administration

Larimar Therapeutics GAAP EPS of -$0.47

Price target increased to US$5.88

High number of new and inexperienced directors

Larimar Therapeutics, Inc., Annual General Meeting, May 10, 2022

Larimar Therapeutics, Inc. Announces Not Stand for Re-Election of Thomas O. Daniel as Board of Director

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Price target decreased to US$13.50

Larimar Therapeutics, Inc. Provides Update on CTI-1601 Clinical Program

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Independent Director recently bought US$496k worth of stock

Larimar Therapeutics, Inc. Reports FDA Clinical Hold on CTI-1601

Larimar under pressure as FDA puts clinical hold on CTI-1601 program

Larimar Therapeutics, Inc. announced that it expects to receive $95.273757 million in funding from Deerfield Management Company, L.P. and other investors

Larimar Therapeutics, Inc. Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia

Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

New 90-day low: US$17.75

Larimar, Avadel, Applied Therapeutics will added to Nasdaq Biotechnology Index

Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update

Larimar completes dosing in Friedreich’s Ataxia, provides program update

Larimar Therapeutics (LRMR) Investor Presentation - Slideshow

New 90-day high: US$22.50

Larimar Therapeutics reports Q3 results

Larimar Therapeutics Announces Formation of Scientific Advisory Board

New 90-day high: US$18.91

New 90-day high - US$16.00

Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Microcap Value Index

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter